These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24809861)

  • 41. Clinical and laboratory-induced colistin-resistance mechanisms in Acinetobacter baumannii.
    Boinett CJ; Cain AK; Hawkey J; Do Hoang NT; Khanh NNT; Thanh DP; Dordel J; Campbell JI; Lan NPH; Mayho M; Langridge GC; Hadfield J; Chau NVV; Thwaites GE; Parkhill J; Thomson NR; Holt KE; Baker S
    Microb Genom; 2019 Feb; 5(2):. PubMed ID: 30720421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure.
    Wang YC; Lee YT; Yang YS; Chen CT; Chiu CH; Yin T; Kuo SC; Chen TL; Lin JC; Wang FD; Fung CP; Chang FY
    Clin Microbiol Infect; 2015 Aug; 21(8):758-64. PubMed ID: 25980356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dissemination of multidrug-resistant Acinetobacter baumannii carrying BlaOxA-23 from hospitals in central Taiwan.
    Lee MH; Chen TL; Lee YT; Huang L; Kuo SC; Yu KW; Hsueh PR; Dou HY; Su IJ; Fung CP
    J Microbiol Immunol Infect; 2013 Dec; 46(6):419-24. PubMed ID: 23010539
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic and virulence characterization of colistin-resistant and colistin-sensitive A. baumannii clinical isolates.
    Leite GC; Stabler RA; Neves P; Perdigão Neto LV; Ruedas Martins RC; Rizek C; Rossi F; Levin AS; Costa SF
    Diagn Microbiol Infect Dis; 2019 Sep; 95(1):99-101. PubMed ID: 31178071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two distinct clones of carbapenem-resistant Acinetobacter baumannii isolates from Korean hospitals.
    Park YK; Choi JY; Jung SI; Park KH; Lee H; Jung DS; Heo ST; Kim SW; Chang HH; Cheong HS; Chung DR; Peck KR; Song JH; Ko KS
    Diagn Microbiol Infect Dis; 2009 Aug; 64(4):389-95. PubMed ID: 19631092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii.
    Galani I; Orlandou K; Moraitou H; Petrikkos G; Souli M
    Int J Antimicrob Agents; 2014 Apr; 43(4):370-4. PubMed ID: 24560919
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy.
    Giannouli M; Di Popolo A; Durante-Mangoni E; Bernardo M; Cuccurullo S; Amato G; Tripodi MF; Triassi M; Utili R; Zarrilli R
    Int J Antimicrob Agents; 2012 Jan; 39(1):58-63. PubMed ID: 22055530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibiotic resistance determinants of multidrug-resistant Acinetobacter baumannii clinical isolates in Algeria.
    Bakour S; Touati A; Sahli F; Ameur AA; Haouchine D; Rolain JM
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):529-31. PubMed ID: 23688522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.
    Kempf M; Rolain JM
    Int J Antimicrob Agents; 2012 Feb; 39(2):105-14. PubMed ID: 22113193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
    Durante-Mangoni E; Signoriello G; Andini R; Mattei A; De Cristoforo M; Murino P; Bassetti M; Malacarne P; Petrosillo N; Galdieri N; Mocavero P; Corcione A; Viscoli C; Zarrilli R; Gallo C; Utili R
    Clin Infect Dis; 2013 Aug; 57(3):349-58. PubMed ID: 23616495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy?
    Simsek F; Gedik H; Yildirmak MT; Iris NE; Türkmen A; Ersoy A; Ersöz M; Gücüyener A
    Indian J Med Microbiol; 2012; 30(4):448-52. PubMed ID: 23183471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii.
    Vila-Farres X; Garcia de la Maria C; López-Rojas R; Pachón J; Giralt E; Vila J
    Clin Microbiol Infect; 2012 Apr; 18(4):383-7. PubMed ID: 21672084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discrepancies in susceptibility testing to colistin in Acinetobacter baumannii: The influence of slow growth and heteroresistance.
    Rodriguez CH; Traglia G; Bastias N; Pandolfo C; Bruni G; Nastro M; Barrios R; Bavastro EM; Rey MC; Marques IA; Heger F; Vay C; Fernandez JS; Ramirez MS; Famiglietti A
    Int J Antimicrob Agents; 2019 Nov; 54(5):587-591. PubMed ID: 31400469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin.
    Katragkou A; Roilides E
    J Clin Microbiol; 2005 Sep; 43(9):4916-7. PubMed ID: 16145177
    [No Abstract]   [Full Text] [Related]  

  • 56. New Mutations Involved in Colistin Resistance in Acinetobacter baumannii.
    Sun B; Liu H; Jiang Y; Shao L; Yang S; Chen D
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32238571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Song JY; Lee J; Heo JY; Noh JY; Kim WJ; Cheong HJ; Hwang IS
    Int J Antimicrob Agents; 2008 Sep; 32(3):281-4. PubMed ID: 18650070
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
    Tripodi MF; Durante-Mangoni E; Fortunato R; Utili R; Zarrilli R
    Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigation of carbapenem-resistant Acinetobacter baumannii isolates in a district hospital in Taiwan.
    Chen CM; Liu PY; Ke SC; Wu HJ; Wu LT
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):394-7. PubMed ID: 19302926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of Acinetobacter baumannii from intensive care units and home care patients in Palermo, Italy.
    Mammina C; Bonura C; Aleo A; Calà C; Caputo G; Cataldo MC; Di Benedetto A; Distefano S; Fasciana T; Labisi M; Sodano C; Palma DM; Giammanco A
    Clin Microbiol Infect; 2011 Nov; 17(11):E12-5. PubMed ID: 21939470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.